Questions About Cancer? 1-800-4-CANCER

High-Dose Vitamin C (PDQ®)

Health Professional Version

Changes to This Summary (10/07/2014)

The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.

Laboratory/Animal/Preclinical Studies

Added text about a study of mouse models of ovarian cancer that found that ascorbate enhanced the tumor inhibitory effect of carboplatin and paclitaxel, first-line chemotherapy used in ovarian cancer (cited Ma et al. as reference 24).

Human/Clinical Studies

Added text about a 2014 phase I/IIA clinical trial that evaluated the toxicities of combining intravenous (IV) ascorbate with carboplatin and paclitaxel in stage III/IV ovarian cancer: 27 patients were randomly assigned to receive either chemotherapy alone or chemotherapy and IV vitamin C concurrently; the addition of IV vitamin C was associated with reduced chemotherapy-related toxicities (cited Ma et al. as reference 14).

Added text to state that trials of high-dose IV vitamin C with other drugs are ongoing.

Adverse Effects

Added Ma et al. as reference 8.

This summary is written and maintained by the PDQ Cancer Complementary and Alternative Medicine Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ NCI's Comprehensive Cancer Database pages.

  • Updated: October 7, 2014